Submitted by Jeffrey Lake on Tue, 03/13/2018 - 6:26pm Thank you for registering for this live webinar. To help you identify your own learning needs and our faculty provide you the best possible educational experience, please complete and submit this short survey before the live webinar. It will take less than 3 minutes to complete. Hazard ratios are frequently given in clinical trials. Which of the following statements about hazard and hazard ratios is/are correct? Please tick all that apply. * The hazard ratio can be defined as, at a particular time interval, the ratio of the risk of a particular outcome in Group A to the risk of outcome in Group B. The term “hazard” refers to the probability that a particular individual, in a clinical trial at a particular time point, undergoes an event (e.g. death) at that time. In a clinical trial examining time to minimal residual disease (MRD), the hazard ratio is the odds that the time to MRD is less in a randomly selected patient from the treatment group than in a randomly selected patient from the control group. There is no difference between risk ratio and hazard ratio. In a particular study of medication X, the hazard rate for relapse was 0.32 (CI, 0.22-0.47; P<0.0001). Which of the following statements is/are correct? Please tick all that apply. * Patients in the treatment group at any time point during the study period were 68% less likely to relapse than patients in the control group. Patients in the treatment group at any time point during the study period were 32% less likely to relapse than patients in the control group. We can be 95% confident that patients in the treatment group were between 53% and 78% less likely to relapse than patients in the control group. We can be 95% confident that patients in the treatment group were between 22% and 47% less likely to relapse than patients in the control group. Which of the following statements is/are correct? Please tick all that apply. * Specificity is the probability that a test will indicate 'disease' in people who actually have the disease or condition the test is designed for. Sensitivity is the probability that a test will indicate 'disease' in people who actually have the disease or condition the test is designed for. Specificity is the fraction of those without the condition being tested for who will have a negative test result. Sensitivity is the fraction of those without the condition being tested for who will have a negative test result. Both sensitivity and specificity are influenced by the prevalence of the disease in the population. Which of the following statements is/are correct? Please tick all that apply. * Positive predictive value is the chance that a person with a positive test truly has the disease or condition tested for. Positive predictive value can be calculated by the formula A(A+B) x100 where A is the number of true positives and B is the number of false positives for a particular test. Negative predictive value can be calculated by the formula D(D+C) = 100 where C is the number of false negatives and C is the number of true negatives for a particular test. If a test is used in a high prevalence setting (e.g. an older age group), the positive predictive value of the test is decreased. If a test is used in a high prevalence setting (e.g. an older age group), the negative predictive value of the test is decreased. To assess the potential benefit of rituximab maintenance 2 months after first-line treatment, patients with follicular lymphoma on rituximab plus chemotherapy regimen were randomised to either observation (no intervention) or rituximab maintenance of weekly 375 mg/m2 intravenously for 8 weeks. Patients on maintenance had progression-free survival (PFS) of 74.9% (95% CI 70.9–78.9) and while those in the observation group had PFS of 57.6% (95% CI 53.2–62.0); 218 progressed; hazard ratio (HR) 0.55, 95% CI 0.44–0.68, p<0.0001. Two years after randomisation, 361 patients (71.5%) in the rituximab maintenance group were in complete or unconfirmed complete response versus 268 (52.2%) in the observation group (p=0.0001). Overall survival did not differ significantly between groups (HR 0.87, 95% CI 0.51–1.47). (Reference: Salles G, et al. Lancet. 2011 Jan 1;377(9759):42-51.) Which of the following statements reflect your interpretation of the above findings? * A patient who received rituximab will have 75% chance of living with the disease without getting worse. Observation (no intervention) reduces the risk of progression by 13%. There is no statistical difference in progression-free survival between the two groups. None of the above How would you rate your knowledge on the following? * PoorFairGoodVery goodExcellent Advantages and limitations of endpoints used in clinical trials Advantages and limitations of endpoints used in clinical trials - Poor Advantages and limitations of endpoints used in clinical trials - Fair Advantages and limitations of endpoints used in clinical trials - Good Advantages and limitations of endpoints used in clinical trials - Very good Advantages and limitations of endpoints used in clinical trials - Excellent Reasons why some endpoints may be appropriate than others when assessing data from clinical trials on NHL Reasons why some endpoints may be appropriate than others when assessing data from clinical trials on NHL - Poor Reasons why some endpoints may be appropriate than others when assessing data from clinical trials on NHL - Fair Reasons why some endpoints may be appropriate than others when assessing data from clinical trials on NHL - Good Reasons why some endpoints may be appropriate than others when assessing data from clinical trials on NHL - Very good Reasons why some endpoints may be appropriate than others when assessing data from clinical trials on NHL - Excellent Common statistical concepts relating to diagnosis and treatment Common statistical concepts relating to diagnosis and treatment - Poor Common statistical concepts relating to diagnosis and treatment - Fair Common statistical concepts relating to diagnosis and treatment - Good Common statistical concepts relating to diagnosis and treatment - Very good Common statistical concepts relating to diagnosis and treatment - Excellent How would you rate your confidence in the following? * Not at all confidentNot very confidentSomewhat confidentConfidentVery confident Applying statistical data in clinical practice Applying statistical data in clinical practice - Not at all confident Applying statistical data in clinical practice - Not very confident Applying statistical data in clinical practice - Somewhat confident Applying statistical data in clinical practice - Confident Applying statistical data in clinical practice - Very confident Appraising the results of clinical trials based on the endpoints used Appraising the results of clinical trials based on the endpoints used - Not at all confident Appraising the results of clinical trials based on the endpoints used - Not very confident Appraising the results of clinical trials based on the endpoints used - Somewhat confident Appraising the results of clinical trials based on the endpoints used - Confident Appraising the results of clinical trials based on the endpoints used - Very confident Communicate expected outcomes of therapy based on results of clinical studies Communicate expected outcomes of therapy based on results of clinical studies - Not at all confident Communicate expected outcomes of therapy based on results of clinical studies - Not very confident Communicate expected outcomes of therapy based on results of clinical studies - Somewhat confident Communicate expected outcomes of therapy based on results of clinical studies - Confident Communicate expected outcomes of therapy based on results of clinical studies - Very confident Leave this field blank
